Home Cart Sign in  
Chemical Structure| 847239-17-2 Chemical Structure| 847239-17-2

Structure of UVI 3003
CAS No.: 847239-17-2

Chemical Structure| 847239-17-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

UVI 3003 is a potent and selective RXR antagonist, used as a tool to test the contribution of RXR to transactivation by a given RXR heterodimer.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of UVI 3003

CAS No. :847239-17-2
Formula : C28H36O4
M.W : 436.58
SMILES Code : O=C(O)/C=C/C1=CC=C(O)C(C2=C(OCCCCC)C=C3C(C)(C)CCC(C)(C)C3=C2)=C1
MDL No. :MFCD18086862
InChI Key :APJSHECCIRQQDV-ZRDIBKRKSA-N
Pubchem ID :44566108

Safety of UVI 3003

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
LEG-derived EECD34 cells 10 μM 24 hours To evaluate the effect of UVI 3003 on Pitx2 expression in LEG-derived EECD34 cells. Results showed that the percentage of Pitx2-positive cells was significantly reduced in UVI 3003-treated cells compared to controls. PMC6546114
EOM-derived EECD34 cells 10 μM 24 hours To evaluate the effect of UVI 3003 on Pitx2 expression in EOM-derived EECD34 cells. Results showed that the percentage of Pitx2-positive cells was significantly reduced in UVI 3003-treated cells compared to controls. PMC6546114
Cos7 cells 10–100 μM 24 hours To evaluate the antagonistic effect of UVI3003 on xRXRα and hRXRα and its activation effect on xPPARγ. Results showed UVI3003 inhibited xRXRα and hRXRα activity (IC50≈0.2 μM) and activated xPPARγ (EC50=12.6 μM), but was almost inactive on hPPARγ and mPPARγ. PMC5183475
COS-7 cells 200 nM 24 hours Compare the antagonistic effects of UVI3003 and β-apo-13-carotenone on 9cRA-induced RXRα transcriptional activity, showing both can antagonize 9cRA activation PMC4246072
Human limbal epithelial cells 0.5 µM, 1.0 µM, 1.5 µM 24 hours and 48 hours To evaluate the effects of UVI 3003 on human limbal epithelial cells, including cell viability and gene expression changes. Results showed that 5 µM UVI led to a dramatic, significant decrease in cell viability. PMC8615883
MCF-7 cells 200 nM 4 hours Investigate the inhibitory effect of UVI3003 on 9cRA-induced caspase 9 gene expression, showing UVI3003 significantly inhibits 9cRA-induced gene expression PMC4246072
COS cells 1 μM To reveal the partial agonist activity of 2c PMC2077255

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Xenopus laevis Embryos Microinjection 1, 5, 10 μM Single injection, continued until neural stage To evaluate the in vivo activation effect of UVI3003 on xPPARγ. Results showed 1 μM UVI3003 significantly activated xPPARγ (~2-fold), and increasing the dose to 5 μM or 10 μM enhanced activation to 3-3.5 fold. PMC5183475

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.45mL

2.29mL

1.15mL

22.91mL

4.58mL

2.29mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories